NUP98 fusion oncoproteins (FO) are a hallmark of childhood acute myeloid leukemia. NUP98 FOs drive leukemogenesis through phase-separated condensate formation and maintenance of an active chromatin landscape at stem cell–associated genes in cooperation with epigenetic regulators. In this study, we show that MYST family histone acetyltransferase (HAT) complex proteins, including KAT6A/MOZ, KAT7/HBO1, and the common KAT6A/7 complex subunit BRPF1, associate with NUP98 FOs on chromatin and within condensates. MYST HATs are molecular dependencies in NUP98-rearranged (NUP98-r) leukemia, and genetic inactivation or pharmacologic inhibition of KAT6A and KAT7 impairs NUP98-r cell fitness. KAT6A/7 inhibition decreased global H3K23ac levels, displaced NUP98::HOXA9 from chromatin at the Meis1 locus, and led to myeloid cell differentiation. Additionally, KAT6A/7 inhibition decreased leukemic burden in multiple NUP98-r leukemia xenograft mouse models, synergized with menin inhibitor treatment, and was efficacious in menin inhibitor–resistant cells. In summary, we show that MYST family HATs are therapeutically actionable dependencies in NUP98-r acute myeloid leukemia. Significance: KAT6A and KAT7 associate with NUP98 FOs to drive leukemogenesis. Inhibition of their HAT activity is an effective therapeutic strategy in NUP98-r leukemias, including those resistant to menin inhibition. Moreover, combined KAT6A/7 and menin inhibition is synergistic, supporting clinical translation to improve outcomes for NUP98 FO–driven leukemias.
Supplementary Table S1. Exonic mutations/indels in Nup98::Kdm5a;Vav-Cre tumors developing after bone marrow transplant Supplementary Table S2. Exonic mutations/indels in spontaneous Nup98::Kdm5a;Vav-Cre tumors Supplementary Table S3. Enrichment/depletion of gRNAs for in vivo epigentic CRISPR/Cas9 screen Supplementary Table S4. Enrichment/depletion of genes for in vivo epigenetic CRISPR/Cas9 screen Supplementary Table S5. Gene ontology analysis for in vivo epigenetic CRISPR/Cas9 screen Supplementary Table S6. Upregulated gene sets in NUP98::HOXA9 mouse leukemia cells after 72-hour treatment with 2 uM SNDX-5613 + 500 nM PF9363 versus vehicle treatment Supplementary Table S7. Downregulated gene sets in NUP98::HOXA9 mouse leukemia cells after 72-hour treatment with 2 uM SNDX-5613 + 500 nM PF9363 versus vehicle treatment Supplementary Table S8. Statistical analysis of Meis1 ChIPseq peaks Supplementary Table S9. Upregulated gene sets in NUP98::KDM5A AMKL PDX (CPCT0021) after treatment with PF9363 versus vehicle Supplementary Table S10. Downregulated gene sets in NUP98::KDM5A AMKL PDX (CPCT0021) after treatment with PF9363 versus vehicle Supplementary Table S11. Average expression of KAT6A and Menin targets in scRNAseq data Supplementary Table S12. Motif analysis of regions with differentially upregulated accessibility after combination treatment versus vehicle Supplementary Table S13. Motif analysis of regions with differentially downregulated accessibility after combination treatment versus vehicle Supplementary Table S14. Primers used in this study Supplementary Table S15. gRNA sequences used in this study Supplementary Table S16. Antibodies used in this study Supplementary Table S17. Fusion oncoprotein amino acid sequences used in RIME